Short answer
Moderna (MRNA) filed its Q1 2025 10-Q quarterly report on May 1, 2025 for the quarter ended Mar 31, 2025. Quarterly revenue was $108M (down 35.3% year over year) with net income of −$971M.
Q1 2025 key financials · XBRL
- Revenue
- $108M
- −35.3% YoY
- Net income
- −$971M
- +17.4% YoY
- Operating margin
- -972.2%
- EPS (diluted)
- −$2.52
- +17.9% YoY
Source: XBRL data from the Moderna (MRNA) Q1 2025 10-Q on SEC EDGAR. USD.
Moderna Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New patent litigation by Arbutus/Genevant filed March 2025 in multiple countries over lipid nanoparticle patents targeting Spikevax and mRESVIA
- Most materially updated risk: PTAB ruling March 2025 found all challenged Moderna patent claims unpatentable in U.S. IPRs, decision subject to appeal
- Regulatory/legal risk: German court ruled Pfizer/BioNTech infringed Moderna patent and owe damages; damages amount pending further proceedings
- Operational risk: Upcoming GSK patent trials for Spikevax and mRESVIA scheduled July and August 2027 affecting market access timing
- No new financial risk disclosures; prior patent litigation-related uncertainties continue impacting potential future monetary damages and costs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Moderna quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.